Cancer epigenetics in clinical practice
V Davalos, M Esteller - CA: a cancer journal for clinicians, 2023 - Wiley Online Library
Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
Acute myeloid leukaemia
CD DiNardo, HP Erba, SD Freeman, AH Wei - The Lancet, 2023 - thelancet.com
Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …
past decade has witnessed an increasingly improved scientific understanding of the …
Recent advances in targeted therapies in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …
for younger patients over the last several decades has improved nearly sixfold with the …
The implications of IDH mutations for cancer development and therapy
CJ Pirozzi, H Yan - Nature reviews Clinical oncology, 2021 - nature.com
Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …
Towards precision medicine for AML
With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
[HTML][HTML] Leukemic stem cells and therapy resistance in acute myeloid leukemia
P Stelmach, A Trumpp - Haematologica, 2023 - ncbi.nlm.nih.gov
A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …
Emerging agents and regimens for AML
H Liu - Journal of hematology & oncology, 2021 - Springer
Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
[PDF][PDF] Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
DA Pollyea, CD DiNardo, ML Arellano, A Pigneux… - Clinical Cancer …, 2022 - AACR
Purpose: To evaluate efficacy and safety of venetoclax+ azacitidine among treatment-naïve
patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). Patients and Methods …
patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). Patients and Methods …